The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Dupilumab in Persistent Asthma with Elevated Eosinophil Levels
Open accessAbstract
BACKGROUND: Moderate-to-severe asthma remains poorly treated. We evaluated the efficacy and safety of dupilumab (SAR231893/REGN668), a fully human monoclonal antibody to the alpha subunit of the interleukin-4 receptor, in patients with persistent, moderate-to-severe asthma and elevated eosinophil levels. METHODS: We enrolled patients with persistent, moderate-to-severe asthma and a blood eosinophil count of at least 300 cells per microliter or a sputum eosinophil level of at least 3% who used medium-dose to high-dose inhaled glucocorticoids plus long-acting beta-agonists (LABAs). We administered dupilumab (300 mg) or placebo subcutaneously once weekly. Patients were instructed to discontinue LABAs at week 4 and to taper and discontinue inhaled glucocorticoids during weeks 6 through 9. Patients received the study drug for 12 weeks or until a protocol-defined asthma exacerbation occurred. The primary end point was the occurrence of an asthma exacerbation; secondary end points included a range of measures of asthma control. Effects on various type 2 helper T-cell (Th2)-associated biomarkers and safety and tolerability were also evaluated. RESULTS: A total of 52 patients were assigned to the dupilumab group, and 52 patients were assigned to the placebo group. Baseline characteristics were similar in the two groups. Three patients had an asthma exacerbation with dupilumab (6%) versus 23 with placebo (44%), corresponding to an 87% reduction with dupilumab (odds ratio, 0.08; 95% confidence interval, 0.02 to 0.28; P<0.001). Significant improvements were observed for most measures of lung function and asthma control. Dupilumab reduced biomarkers associated with Th2-driven inflammation. Injection-site reactions, nasopharyngitis, nausea, and headache occurred more frequently with dupilumab than with placebo. CONCLUSIONS: In patients with persistent, moderate-to-severe asthma and elevated eosinophil levels who used inhaled glucocorticoids and LABAs, dupilumab therapy, as compared with placebo, was associated with fewer asthma exacerbations when LABAs and inhaled glucocorticoids were withdrawn, with improved lung function and reduced levels of Th2-associated inflammatory markers. (Funded by Sanofi and Regeneron Pharmaceuticals; ClinicalTrials.gov number, NCT01312961.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Asthma phenotypes: the evolution from clinical to molecular approaches
Wenzel, S. E. (2012) · Nature Medicine · doi:10.1038/nm.2678 · Cited by 2,412
Self-citationPavord, I. D., Korn, S., Howarth, P., Bleecker, E. R., Buhl, R., Keene, O. N., Ortega, H., & Chanez, P. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60988-x · Cited by 2,221
Mepolizumab and Exacerbations of Refractory Eosinophilic Asthma
Haldar, P., Brightling, C. E., Hargadon, B., Gupta, S., Monteiro, W., Sousa, A., Marshall, R. P., Bradding, P., Green, R. H., Wardlaw, A. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808991 · Cited by 1,871
Requirement for IL-13 Independently of IL-4 in Experimental Asthma
Grünig, G., Warnock, M., Wakil, A. E., Venkayya, R., Brombacher, F., Rennick, D. M., Sheppard, D., Mohrs, M., Donaldson, D. D., Locksley, R. M., et al. (1998) · Science · doi:10.1126/science.282.5397.2261 · Cited by 1,849
T-helper Type 2–driven Inflammation Defines Major Subphenotypes of Asthma
Woodruff, P. G., Modrek, B., Choy, D. F., Jia, G., Abbas, A. R., Ellwanger, A., Arron, J. R., Koth, L. L., & Fahy, J. V. (2009) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200903-0392oc · Cited by 1,803
Psychometric validity of the 22‐item Sinonasal Outcome Test
Hopkins, C., Gillett, S., Slack, R., Lund, V. J., & Browne, J. P. (2009) · Clinical Otolaryngology · doi:10.1111/j.1749-4486.2009.01995.x · Cited by 1,621
Can Guideline-defined Asthma Control Be Achieved?: The Gaining Optimal Asthma ControL Study
Bateman, E. D., Boushey, H. A., Bousquet, J., Busse, W. W., Clark, T. J. H., Pauwels, R. A., & Pedersen, S. E. (2004) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200401-033oc · Cited by 1,594
Lebrikizumab Treatment in Adults with Asthma
Corren, J., Lemanske, R. F., Hanania, N. A., Korenblat, P. E., Parsey, M. V., Arron, J. R., Harris, J. M., Scheerens, H., Wu, L. C., Su, Z., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1106469 · Cited by 1,514
Mepolizumab for Prednisone-Dependent Asthma with Sputum Eosinophilia
Nair, P., Pizzichini, M. M. M., Kjarsgaard, M., Inman, M. D., Efthimiadis, A., Pizzichini, E., Hargreave, F. E., & O'Byrne, P. M. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805435 · Cited by 1,356
Juniper, E. F., Svensson, K., Mörk, A.-C., & Ståhl, E. (2005) · Respiratory Medicine · doi:10.1016/j.rmed.2004.10.008 · Cited by 929
Cited by
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
Simpson, E. L., Bieber, T., Guttman-Yassky, E., Beck, L. A., Blauvelt, A., Cork, M. J., Silverberg, J. I., Deleuran, M., Kataoka, Y., Lacour, J.-P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1610020 · Cited by 2,110
Self-citationDevelopment of therapeutic antibodies for the treatment of diseases
Lu, R.-M., Hwang, Y.-C., Liu, I.-J., Lee, C.-C., Tsai, H.-Z., Li, H.-J., & Wu, H.-C. (2020) · Journal of Biomedical Science · doi:10.1186/s12929-019-0592-z · Cited by 2,085
Lambrecht, B. N., & Hammad, H. (2015) · Nature Immunology · doi:10.1038/ni.3049 · Cited by 1,673
Type 2 inflammation in asthma — present in most, absent in many
Fahy, J. V. (2015) · Nature Reviews Immunology · doi:10.1038/nri3786 · Cited by 1,654
Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis
Beck, L. A., Thaçi, D., Hamilton, J. D., Graham, N. M., Bieber, T., Rocklin, R., Ming, J. E., Ren, H., Kao, R., Simpson, E., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1314768 · Cited by 1,421
Self-citationBlauvelt, A., de Bruin-Weller, M., Gooderham, M., Cather, J. C., Weisman, J., Pariser, D., Simpson, E. L., Papp, K. A., Hong, H. C.-H., Rubel, D., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31191-1 · Cited by 1,261
Self-citationEfficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma
Rabe, K. F., Nair, P., Brusselle, G., Maspero, J. F., Castro, M., Sher, L., Zhu, H., Hamilton, J. D., Swanson, B. N., Khan, A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1804093 · Cited by 1,184
Self-citationThe basic immunology of asthma
Hammad, H., & Lambrecht, B. N. (2021) · Cell · doi:10.1016/j.cell.2021.02.016 · Cited by 1,105
Treatable traits: toward precision medicine of chronic airway diseases
Agusti, A., Bel, E., Thomas, M., Vogelmeier, C., Brusselle, G., Holgate, S., Humbert, M., Jones, P., Gibson, P. G., Vestbo, J., et al. (2016) · European Respiratory Journal · doi:10.1183/13993003.01359-2015 · Cited by 1,083
Type 2 immunity in tissue repair and fibrosis
Gieseck, R. L., Wilson, M. S., & Wynn, T. A. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.90 · Cited by 1,055
After asthma: redefining airways diseases
Pavord, I. D., Beasley, R., Agusti, A., Anderson, G. P., Bel, E., Brusselle, G., Cullinan, P., Custovic, A., Ducharme, F. M., Fahy, J. V., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)30879-6 · Cited by 1,073
Self-citationLambrecht, B. N., Hammad, H., & Fahy, J. V. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.018 · Cited by 1,039
Wenzel, S., Castro, M., Corren, J., Maspero, J., Wang, L., Zhang, B., Pirozzi, G., Sutherland, E. R., Evans, R. R., Joish, V. N., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30307-5 · Cited by 985
Self-citationAkdis, C. A. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-021-00538-7 · Cited by 981
Bachert, C., Mannent, L., Naclerio, R. M., Mullol, J., Ferguson, B. J., Gevaert, P., Hellings, P., Jiao, L., Wang, L., Evans, R. R., et al. (2016) · JAMA · doi:10.1001/jama.2015.19330 · Cited by 794
Self-citationEffects of an Anti-TSLP Antibody on Allergen-Induced Asthmatic Responses
Gauvreau, G. M., O'Byrne, P. M., Boulet, L.-P., Wang, Y., Cockcroft, D., Bigler, J., FitzGerald, J. M., Boedigheimer, M., Davis, B. E., Dias, C., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402895 · Cited by 789
Targeting key proximal drivers of type 2 inflammation in disease
Gandhi, N. A., Bennett, B. L., Graham, N. M. H., Pirozzi, G., Stahl, N., & Yancopoulos, G. D. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd4624 · Cited by 766
Self-citationAnti-inflammatory and immune-regulatory cytokines in rheumatoid arthritis
Chen, Z., Bozec, A., Ramming, A., & Schett, G. (2019) · Nature Reviews Rheumatology · doi:10.1038/s41584-018-0109-2 · Cited by 719
Guttman-Yassky, E., Bissonnette, R., Ungar, B., Suárez-Fariñas, M., Ardeleanu, M., Esaki, H., Suprun, M., Estrada, Y., Xu, H., Peng, X., et al. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.08.022 · Cited by 697
Self-citationType 2 cytokines: mechanisms and therapeutic strategies
Wynn, T. A. (2015) · Nature Reviews Immunology · doi:10.1038/nri3831 · Cited by 678
Food allergy: immune mechanisms, diagnosis and immunotherapy
Yu, W., Freeland, D. M. H., & Nadeau, K. C. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2016.111 · Cited by 659
Holgate, S. T., Wenzel, S., Postma, D. S., Weiss, S. T., Renz, H., & Sly, P. D. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.25 · Cited by 652
Self-citationOmalizumab for asthma in adults and children
Normansell, R., Walker, S., Milan, S. J., Walters, E. H., & Nair, P. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003559.pub4 · Cited by 651
Allergic inflammatory memory in human respiratory epithelial progenitor cells
(2018) · doi:10.1038/s41586-018-0449-8 · Cited by 599
Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study
Price, D. B., Rigazio, A., Campbell, J. D., Bleecker, E. R., Corrigan, C. J., Thomas, M., Wenzel, S. E., Wilson, A. M., Small, M. B., Gopalan, G., et al. (2015) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(15)00367-7 · Cited by 591
Self-citationThaçi, D., Simpson, E. L., Beck, L. A., Bieber, T., Blauvelt, A., Papp, K., Soong, W., Worm, M., Szepietowski, J. C., Sofen, H., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00388-8 · Cited by 572
Self-citationChronic Rhinosinusitis with Nasal Polyps
Stevens, W. W., Schleimer, R. P., & Kern, R. C. (2016) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2016.04.012 · Cited by 571
Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort
Shaw, D. E., Sousa, A. R., Fowler, S. J., Fleming, L. J., Roberts, G., Corfield, J., Pandis, I., Bansal, A. T., Bel, E. H., Auffray, C., et al. (2015) · European Respiratory Journal · doi:10.1183/13993003.00779-2015 · Cited by 555
Le Floc’h, A., Allinne, J., Nagashima, K., Scott, G., Birchard, D., Asrat, S., Bai, Y., Lim, W. K., Martin, J., Huang, T., et al. (2020) · Allergy · doi:10.1111/all.14151 · Cited by 545
Self-citationCommonality of the IL-4/IL-13 pathway in atopic diseases
Gandhi, N. A., Pirozzi, G., & Graham, N. M. H. (2017) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2017.1298443 · Cited by 493
Self-citationIL-4 and IL-13 signaling in allergic airway disease
Gour, N., & Wills-Karp, M. (2015) · Cytokine · doi:10.1016/j.cyto.2015.05.014 · Cited by 490
de Bruin-Weller, M., Thaçi, D., Smith, C. H., Reich, K., Cork, M. J., Radin, A., Zhang, Q., Akinlade, B., Gadkari, A., Eckert, L., et al. (2018) · British Journal of Dermatology · doi:10.1111/bjd.16156 · Cited by 479
Self-citationBal, S. M., Bernink, J. H., Nagasawa, M., Groot, J., Shikhagaie, M. M., Golebski, K., van Drunen, C. M., Lutter, R., Jonkers, R. E., Hombrink, P., et al. (2016) · Nature Immunology · doi:10.1038/ni.3444 · Cited by 471
Hamilton, J. D., Suárez-Fariñas, M., Dhingra, N., Cardinale, I., Li, X., Kostic, A., Ming, J. E., Radin, A. R., Krueger, J. G., Graham, N., et al. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2014.10.013 · Cited by 469
Self-citationConjunctivitis in dupilumab clinical trials
Akinlade, B., Guttman‐Yassky, E., Bruin‐Weller, M., Simpson, E. L., Blauvelt, A., Cork, M. J., Prens, E., Asbell, P., Akpek, E., Corren, J., et al. (2019) · British Journal of Dermatology · doi:10.1111/bjd.17869 · Cited by 442
Self-citationVirchow, J. C., Backer, V., Kuna, P., Prieto, L., Nolte, H., Villesen, H. H., Ljørring, C., Riis, B., & de Blay, F. (2016) · JAMA · doi:10.1001/jama.2016.3964 · Cited by 436
Wagener, A. H., de Nijs, S. B., Lutter, R., Sousa, A. R., Weersink, E. J. M., Bel, E. H., & Sterk, P. J. (2015) · Thorax · doi:10.1136/thoraxjnl-2014-205634 · Cited by 429
Targeting cytokines to treat asthma and chronic obstructive pulmonary disease
Barnes, P. J. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0006-6 · Cited by 418
Treatment of atopic dermatitis with tralokinumab, an anti–IL-13 mAb
Wollenberg, A., Howell, M. D., Guttman-Yassky, E., Silverberg, J. I., Kell, C., Ranade, K., Moate, R., & van der Merwe, R. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.05.029 · Cited by 409
Interleukin‐13: Targeting an underestimated cytokine in atopic dermatitis
Bieber, T. (2020) · Allergy · doi:10.1111/all.13954 · Cited by 382
Hanania, N. A., Noonan, M., Corren, J., Korenblat, P., Zheng, Y., Fischer, S. K., Cheu, M., Putnam, W. S., Murray, E., Scheerens, H., et al. (2015) · Thorax · doi:10.1136/thoraxjnl-2014-206719 · Cited by 381
Brightling, C. E., Chanez, P., Leigh, R., O'Byrne, P. M., Korn, S., She, D., May, R. D., Streicher, K., Ranade, K., & Piper, E. (2015) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(15)00197-6 · Cited by 369
Airway Mucus and Asthma: The Role of MUC5AC and MUC5B
Bonser, L., & Erle, D. (2017) · Journal of Clinical Medicine · doi:10.3390/jcm6120112 · Cited by 359
Robinson, D., Humbert, M., Buhl, R., Cruz, A. A., Inoue, H., Korom, S., Hanania, N. A., & Nair, P. (2017) · Clinical & Experimental Allergy · doi:10.1111/cea.12880 · Cited by 357
Fajt, M. L., & Wenzel, S. E. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2014.12.1871 · Cited by 353
Self-citationPhenotypes in obstructive sleep apnea: A definition, examples and evolution of approaches
Zinchuk, A. V., Gentry, M. J., Concato, J., & Yaggi, H. K. (2017) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2016.10.002 · Cited by 350
Beale, J., Jayaraman, A., Jackson, D. J., Macintyre, J. D. R., Edwards, M. R., Walton, R. P., Zhu, J., Ching, Y. M., Shamji, B., Edwards, M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3009124 · Cited by 332
Principles and therapeutic applications of adaptive immunity
Chi, H., Pepper, M., & Thomas, P. G. (2024) · Cell · doi:10.1016/j.cell.2024.03.037 · Cited by 330
Eosinophilic airway inflammation: role in asthma and chronic obstructive pulmonary disease
George, L., & Brightling, C. E. (2016) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622315609251 · Cited by 326
Allergen-Induced Asthmatic Responses Modified by a GATA3-Specific DNAzyme
Krug, N., Hohlfeld, J. M., Kirsten, A.-M., Kornmann, O., Beeh, K. M., Kappeler, D., Korn, S., Ignatenko, S., Timmer, W., Rogon, C., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411776 · Cited by 321
Current and future treatment options for adult chronic rhinosinusitis: Focus on nasal polyposis
Bachert, C., Zhang, L., & Gevaert, P. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.10.010 · Cited by 317
Farne, H. A., Wilson, A., Powell, C., Bax, L., & Milan, S. J. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010834.pub3 · Cited by 315
Allergic Endotypes and Phenotypes of Asthma
Akar-Ghibril, N., Casale, T., Custovic, A., & Phipatanakul, W. (2020) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2019.11.008 · Cited by 312
Alternatively activated macrophages; a double-edged sword in allergic asthma
Abdelaziz, M. H., Abdelwahab, S. F., Wan, J., Cai, W., Huixuan, W., Jianjun, C., Kumar, K. D., Vasudevan, A., Sadek, A., Su, Z., et al. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02251-w · Cited by 287
Baseline Features of the Severe Asthma Research Program (SARP III) Cohort: Differences with Age
Teague, W. G., Phillips, B. R., Fahy, J. V., Wenzel, S. E., Fitzpatrick, A. M., Moore, W. C., Hastie, A. T., Bleecker, E. R., Meyers, D. A., Peters, S. P., et al. (2018) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2017.05.032 · Cited by 280
Self-citationInnate and adaptive type 2 immunity in lung allergic inflammation
Kubo, M. (2017) · Immunological Reviews · doi:10.1111/imr.12557 · Cited by 269
Real-World Effectiveness of Benralizumab in Severe Eosinophilic Asthma
Kavanagh, J. E., Hearn, A. P., Dhariwal, J., d’Ancona, G., Douiri, A., Roxas, C., Fernandes, M., Green, L., Thomson, L., Nanzer, A. M., et al. (2021) · Chest · doi:10.1016/j.chest.2020.08.2083 · Cited by 263
Targeting the interleukin pathway in the treatment of asthma
Chung, K. F. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00157-9 · Cited by 261
Agarwal, R., Sehgal, I. S., Muthu, V., Denning, D. W., Chakrabarti, A., Soundappan, K., Garg, M., Rudramurthy, S. M., Dhooria, S., Armstrong-James, D., et al. (2024) · European Respiratory Journal · doi:10.1183/13993003.00061-2024 · Cited by 261
Dissecting childhood asthma with nasal transcriptomics distinguishes subphenotypes of disease
Poole, A., Urbanek, C., Eng, C., Schageman, J., Jacobson, S., O'Connor, B. P., Galanter, J. M., Gignoux, C. R., Roth, L. A., Kumar, R., et al. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.11.025 · Cited by 260
Asthma: pathogenesis and novel drugs for treatment
Olin, J. T., & Wechsler, M. E. (2014) · BMJ · doi:10.1136/bmj.g5517 · Cited by 256
Deleuran, M., Thaçi, D., Beck, L. A., de Bruin-Weller, M., Blauvelt, A., Forman, S., Bissonnette, R., Reich, K., Soong, W., Hussain, I., et al. (2020) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2019.07.074 · Cited by 255
Self-citationBiologics and airway remodeling in severe asthma
Varricchi, G., Ferri, S., Pepys, J., Poto, R., Spadaro, G., Nappi, E., Paoletti, G., Virchow, J. C., Heffler, E., & Canonica, W. G. (2022) · Allergy · doi:10.1111/all.15473 · Cited by 254
Faiz, S., Giovannelli, J., Podevin, C., Jachiet, M., Bouaziz, J.-D., Reguiai, Z., Nosbaum, A., Lasek, A., Ferrier le Bouedec, M.-C., Du Thanh, A., et al. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2019.02.053 · Cited by 210
Strategies targeting the IL-4/IL-13 axes in disease
May, R. D., & Fung, M. (2015) · Cytokine · doi:10.1016/j.cyto.2015.05.018 · Cited by 166
Recent advances in understanding the role of IL-4 signaling
Keegan, A. D., Leonard, W. J., & Zhu, J. (2021) · Faculty Reviews · doi:10.12703/r/10-71 · Cited by 154
Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics
Golay, J., Semenzato, G., Rambaldi, A., Foà, R., Gaidano, G., Gamba, E., Pane, F., Pinto, A., Specchia, G., Zaja, F., et al. (2013) · mAbs · doi:10.4161/mabs.26008 · Cited by 148
Gieseck, R. L., Ramalingam, T. R., Hart, K. M., Vannella, K. M., Cantu, D. A., Lu, W.-Y., Ferreira-González, S., Forbes, S. J., Vallier, L., & Wynn, T. A. (2016) · Immunity · doi:10.1016/j.immuni.2016.06.009 · Cited by 132
EAACI position statement on asthma exacerbations and severe asthma
Custovic, A., Johnston, S. L., Pavord, I., Gaga, M., Fabbri, L., Bel, E. H., Le Souëf, P., Lötvall, J., Demoly, P., Akdis, C. A., et al. (2013) · Allergy · doi:10.1111/all.12275 · Cited by 127
Adcock, I. M., & Mumby, S. (2016) · Handbook of experimental pharmacology · doi:10.1007/164_2016_98 · Cited by 131
Menzies-Gow, A., Ponnarambil, S., Downie, J., Bowen, K., Hellqvist, Å., & Colice, G. (2020) · Respiratory Research · doi:10.1186/s12931-020-01541-7 · Cited by 71
Novel Biologicals for the Treatment of Allergic Diseases and Asthma
Tan, H.-T. T., Sugita, K., & Akdis, C. A. (2016) · Current Allergy and Asthma Reports · doi:10.1007/s11882-016-0650-5 · Cited by 68
Effective use of dupilumab in managing systemic allergic contact dermatitis
Joshi, S. R., & Khan, D. A. (2018) · Dermatitis® · doi:10.1097/der.0000000000000409 · Cited by 58
Edwards, M. R., Saglani, S., Schwarze, J., Skevaki, C., Smith, J. A., Ainsworth, B., Almond, M., Andreakos, E., Belvisi, M. G., Chung, K. F., et al. (2017) · European Respiratory Journal · doi:10.1183/13993003.02448-2016 · Cited by 55
Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or Asthma
Bansal, A., Simpson, E. L., Paller, A. S., Siegfried, E. C., Blauvelt, A., de Bruin-Weller, M., Corren, J., Sher, L., Guttman-Yassky, E., Chen, Z., et al. (2021) · American Journal of Clinical Dermatology · doi:10.1007/s40257-020-00577-1 · Cited by 52
Self-citationBretherick, A. D., Canela-Xandri, O., Joshi, P. K., Clark, D. W., Rawlik, K., Boutin, T. S., Zeng, Y., Amador, C., Navarro, P., Rudan, I., et al. (2020) · PLOS Genetics · doi:10.1371/journal.pgen.1008785 · Cited by 42
Anderson, A., Cherfane, C., Click, B., Ramos-Rivers, C., Koutroubakis, I. E., Hashash, J. G., Babichenko, D., Tang, G., Dunn, M., Barrie, A., et al. (2022) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izab031 · Cited by 40
Florian, P., Flechsenhar, K. R., Bartnik, E., Ding‐Pfennigdorff, D., Herrmann, M., Bryce, P. J., & Nestle, F. O. (2020) · Experimental Dermatology · doi:10.1111/exd.13942 · Cited by 20
Refractory asthma - beyond step 5, the role of new and emerging adjuvant therapies
Kane, B., Fowler, S. J., & Niven, R. (2015) · Chronic Respiratory Disease · doi:10.1177/1479972314562210 · Cited by 15
Metadata
- Authors
- Wenzel, S., Ford, L., Pearlman, D., Spector, S., Sher, L., Skobieranda, F., Wang, L., Kirkesseli, S., Rocklin, R., Bock, B., Hamilton, J., Ming, J. E., Radin, A., Stahl, N., Yancopoulos, G. D., Graham, N., & Pirozzi, G.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-06-27
- Volume
- 368
- Issue
- 26
- Pages
- 2455-2466
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2167829087
- Cited by
- 1,320
- References
- 25
- FWCI
- 89.36
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.